Stocks Industrials ALMR
NASDAQ · IndustrialsAlamar Biosciences, Inc. (ALMR)
At September 30, 2026 it held $121.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Alamar Biosciences, Inc.
- Net worth
- Alamar Biosciences, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $303.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alamar Biosciences, Inc.'s next report is expected around February 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Alamar Biosciences, Inc. does
Alamar Biosciences, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker ALMR.
Earnings: every quarter and the next report date
Latest SEC filings
What Alamar Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 68% to $33.5M versus the same quarter last year; diluted EPS -$0.19 versus -$0.69.
- November 3, 2026
- September 1, 2026
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 82% to $29.4M versus the same quarter last year; diluted EPS -$0.22 versus -$0.62.
- August 10, 2026
- July 15, 2026Other event 8-K
- July 7, 2026Activist stake changed SCHEDULE 13D/A
- July 2, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Alamar Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $44.6M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 1,946 | $58.2K |
| November 3, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 72,301 | $2.2M |
| November 3, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 16,870 | $504.2K |
| November 3, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 20,196 | $603.7K |
| November 2, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 763 | $22.8K |
| November 2, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 3 | $91.9 |
| November 2, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 28,404 | $847.6K |
| November 2, 2026 | Qiming Corporate GP VI, Ltd.10% owner | Soldindirect | 131 | $4K |
Who owns ALMR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Qiming Corporate GP VI, Ltd13G, passive with 6 related filers | 10.2% | August 11, 2026 |
| Nicholas Naclerio13D, may seek influence with 4 related filers | 9.6% | April 23, 2026 |
| Daqing Cai13G, passive with 4 related filers | 7.2% | July 2, 2026 |
| Yuling Luo13G, passive | 6.4% | August 13, 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P.13D, may seek influence with 2 related filers | 6.1% | July 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 86 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Sands Capital Alternatives, LLC | 4,230,926 | new |
| Samsara Biocapital, LLC | 2,480,310 | new |
| ARK Investment Management LLC | 1,373,959 | new |
| Braidwell LP | 1,083,983 | new |
| Alliancebernstein L.P. | 1,003,077 | new |
| Hhlr Advisors, Ltd. | 956,462 | new |
| BlackRock, Inc. | 911,445 | new |
| Millennium Management LLC | 865,764 | new |
| Fmr LLC | 829,424 | new |
| Pura Vida Investments, LLC | 755,909 | new |
| Emerald Advisers, LLC | 647,183 | new |
| Artisan Partners Limited Partnership | 613,744 | new |
| Deerfield Management Company, L.P. | 600,000 | new |
| Vanguard Capital Management LLC | 463,385 | new |
| Farallon Capital Management, L.L.C. | 462,900 | new |
| Wellington Management Group Llp | 457,974 | new |
| Emerald Mutual Fund Advisers Trust | 422,127 | new |
| Ameriprise Financial Inc | 418,965 | new |
| Geode Capital Management, LLC | 330,134 | new |
| Woodline Partners LP | 243,320 | new |
Insiders
9 insiders reported holding 7,158,732 shares in total, about $200.8M at the last price.
| Holder | Shares |
|---|---|
| Luo YulingChief Executive Officer, Director | 3,164,7261,224,152 held indirectly |
| Qiming Corporate GP VI, Ltd.10% owner | 1,650,3541,650,354 held indirectly |
| Chen ShipingChief Operating Officer, Director | 760,105 |
| Naclerio NicholasDirector | 512,762507,076 held indirectly |
| Illumina Innovation Fund II GP, L.L.C.10% owner | 507,076507,076 held indirectly |
| White Timothy OgdenPresident | 491,803 |
| McAnear Justin J.Chief Financial Officer | 37,220 |
| Brottem John L.General Counsel | 29,000 |
| Ragusa Robert PDirector | 5,686 |
Questions about ALMR
What does Alamar Biosciences, Inc. do?
Alamar Biosciences, Inc. is a company in the Industrials sector, listed on NASDAQ as ALMR. Its shares trade on NASDAQ under the ticker ALMR.
What is Alamar Biosciences, Inc.'s net worth?
Alamar Biosciences, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $303.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
When did Alamar Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Alamar Biosciences, Inc.'s next earnings report?
Alamar Biosciences, Inc.'s next report is expected around February 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ALMR with
Follow ALMR
Get an email when Alamar Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alamar Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.